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Background: MicroRNA-21 (miR-21) has been suggested to play a significant role in the prognosis of carcinoma.
The recognition of novel biomarkers for the prediction of cancer outcomes is urgently required. However, the
potential prognostic value of miR-21 in various types of human malignancy remains controversial. The present
meta-analysis summarises and analyses the associations between miR-21 status and overall survival (OS) in a variety
of tumours.
Methods: Eligible published studies were identified by searching the PubMed and Chinese Biomedicine databases.
The patients’ clinical characteristics and survival results were pooled, and a pooled hazard ratio (HR) with 95%
confidence intervals (95% CI) was used to calculate the strength of this association. A random-effects model was
adopted, and then, meta-regression and subgroup analyses were performed. In addition, an analysis of publication
bias was also conducted.
Results: Twenty-seven eligible articles (including 31 studies) were identified that included survival data for 3273
patients. The pooled HR suggested that high miR-21 was clearly related to worse overall survival (HR = 2.27, 95% CI:
1.81-2.86), with a heterogeneity measure index of I2 = 76.0%, p = 0.001, showing that miR-21 might be a considerable
prognostic factor for poor survival in cancer patients.
Conclusions: MiR-21 might be a potentially useful biomarker for predicting cancer prognosis in future clinical
applications.
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MicroRNAs (miRNAs) are a class of endogenous, small
(approximately 22 nucleotides), non-coding, highly con-
served and single-stranded RNAs that negatively regulate
mRNA and protein expression by forming base-pairs with
target mRNAs and sequentially induce translational re-
pression and mRNA cleavage [1,2]. More than 50% of
miRNA genes are frequently located at fragile sites and
genomic regions involved in multiple cancers, which sug-
gests their potentially important and complex role in can-
cer [3]. Previous studies have showed that miRNAs are
involved in regulating many urgent biological processes,
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unless otherwise stated.cell-cycle control, development, apoptosis and tumour de-
velopment [4,5]. It has been reported that if the target
gene of the miRNA is a tumour suppressor or oncogene,
the aberrant expression of the miRNA will lead to disrup-
tions in the miRNA-target genes and induce a disease sta-
tus and even cancer development [6].
MiR-21 stands out as the most commonly dramatically
up-regulated miRNA in both solid and haematological ma-
lignancies [7], and it is associated with clinicopathological
factors in a considerable proportion of human malignan-
cies [8-15]. In addition, extensive studies have implicated
its integral role in tumour pathogenesis and during all
other stages of carcinogenesis. Some studies have con-
firmed that miR-21 down-regulates four tumour suppres-
sor genes: maspin, programmed cell death 4 (PDCD4),
tropomyosin1 (TPM1) and phosphatase and tensin homo-
log (PTEN), which are all involved in tumourigenesis, celltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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some evidence that indicates that the level of miR-21 ex-
pression is significantly associated with the prognosis of
tumour patients, suggesting that it might serve as a prog-
nostic marker for human malignancy [21].
Prognostic factors may identify subsets of patients with
a worse prognosis and facilitate the selection of a more
aggressive treatment strategy. The discovery of molecu-
lar biological prognostic factors would be helpful in a
more accurate prediction of clinical outcome and may
also reveal novel predictive factors and therapeutic tar-
gets [22]. However, the existing prognostic and predict-
ive factors still need more proof, and they should be
applied with caution when choosing the optimal adju-
vant treatment. It is of great importance to balance the
threshold of determining if patients need further treat-
ment to avoid overtreatment or insufficient treatment.
The prognostic role of miR-21 might potentially enhance
the preoperative selection of low-risk patients who can
be treated with resection alone, while directing high-risk
cases to systemic treatment [23]. Above all, due to the
apparent difference in expression between normal and
malignant tissue and its causal role in cancer develop-
ment, miR-21 is currently attracting considerable atten-
tion and has led to a number of studies reporting the
relationship between miR-21 status and clinical out-
comes among a wide variety of tumour types. However,
most studies were conducted with a small sample size,
and the observed associations were discordant. There-
fore, we performed a literature-based meta-analysis of
eligible studies to produce evidence-based results on the
prognostic role of miR-21 in multiple types of malignant
tumours to clarify this question and identify further re-
search needs.
Methods
We performed this meta-analysis according to the guide-
lines of the Meta-analysis of Observational Studies in
Epidemiology group (MOOSE) [24] and PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and Meta-
analysis) [25].
Search strategy and selection criteria
Studies were identified via an electronic search of PubMed
and Chinese Biomedicine databases using the following
keywords: (microRNA-21 OR miR-21 OR miR-21 OR
mir21) AND (prognosis OR prognostic OR outcome OR
mortality OR survival). The search ended on June 19th,
2014, and no lower date limit was used. The search was
performed without language restriction. We also con-
tacted some of the authors of the identified studies to ob-
tain some unavailable data. Reference lists from relevant
primary studies and review articles were also scanned for
additional relevant publications. To ensure the quality ofthe meta-analysis, two authors (Li Jinhui & Wang Wenjia)
independently performed the search and identification ac-
cording to the standardised approach, and the final selec-
tion of a study for inclusion in the meta-analysis was
reached by consensus.
To be eligible for inclusion, studies met the following
criteria: (I) they reported research on patients with any
type of carcinoma; (II) they measured the expression of
miR-21 and reported the corresponding cut-off value; (III)
they investigated the association between miR-21 expres-
sion and overall survival (OS); (IV) the hazard ratio (HR)
for overall survival according to miR-21 status either had
to be reported or could be calculated from the information
presented; (V) the study sample size was higher than
twenty individuals; (VI) when the same author or group
reported results obtained from the same patient popula-
tion in more than one article, the most recent report or
the most informative one was included in this analysis to
avoid overlapping between cohorts; and (VII) they used
tissue samples (without any neoadjuvant therapy) obtained
from surgically resected tumours and corresponding non-
cancerous or normal tissues for comparison.Definition, data extraction and methodological
assessment
Overall survival was defined as the interval between the
medical treatment and the death of patients or the last
observation.
All eligible publications were reviewed by two reviewers
(Li Jinhui & Wang Wenjia), and they then extracted the
study data based on a predefined standardised form in-
cluding the characteristics of eligible studies, the baseline
information of patients and the survival analysis data
(Additional file 1: Table S1). Disagreements were resolved
by discussion. The extracted information was summarised
in a consistent manner to prevent bias. Survival outcome
data were synthesised using the time-to-event hazard ratio
(HR) and the 95% confidence intervals (95% CI) from the
original article as the effective measure. If this information
was not available, sending an email to the authors for
complementary information was our first choice. If the
Kaplan-Meier survival curves were available, we used the
method previously described by Parmar et al. and Tierney
et al. to estimate HR and its corresponding 95% CI [26].
Additional data were extracted from the studies, including
the first author, publication year, number of patients, mean
age, follow-up, cancer type (system), cancer category and
stage.
Furthermore, a methodological assessment of each
study was also conducted by two investigators (Li Jinhui
& Wang Wenjia) according to REMARK guidelines [27].
Disagreements were adjudicated by a third investigator
(Zhu Wei) after referring to the original articles.
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To quantitatively combine the survival data, we ex-
tracted the HRs and their 95% CIs to assess the impact
of the miR-21 status on tumour prognosis. A combined
HR > 1 implied a worse survival for the group with miR-
21 overexpression. This negative impact of miR-21 on
survival was considered statistically significant if the 95%
CI for the combined HR did not overlap 1. To assess
heterogeneity among the studies, we used I2 statistics,
which describe the proportion of total variation in meta-
analysis estimates due to between-study heterogeneity.
The variation is measured from 0-100%, with increasing
I2 values indicating a larger impact of between-study
heterogeneity in the meta-analysis [28]. The results were
considered statistically significant if the p value was less
than 0.05 and was quantified using the I2 metric (I2 <
25%, no heterogeneity; I2 = 25-50%, moderate hetero-
geneity; and I2 > 50%, strong heterogeneity) [29]. If het-
erogeneity was found, the random-effects model was
applied. Otherwise, the fixed-effects model was used. In
addition, we also investigated potential sources of het-
erogeneity through meta-regression analysis and sub-
group analysis. Sensitivity analyses were performed with
the exclusion of studies that had the highest weight, the
highest or lowest estimates, the largest sample size, or
the studies for which data were acquired through calcu-
lation. The Begg’s funnel plot method was used to inves-
tigate any possible publication bias. For all analyses, a
two-sided p value less than 0.05 was considered to be
statistically significant. All analyses were performed
using STATA version 12.0 software (Stata Corporation,
College Station, TX).
Results
Literature selection and characteristics
A total of 288 potentially relevant citations, including
256 reports in English and 32 in Chinese, were retrieved
after the initial database search using the search strat-
egies described previously. The titles and abstracts of
relevant articles were read by two authors independently.
A total of 185 citations were excluded from analysis after
the first screening based on abstracts or titles (39 were
review articles; 25 were irrelevant to cancer; 54 dealt
with cell lines or animals; 41 were irrelevant to progno-
sis; 14 did not study tumour tissues; 12 were unrelated
to miR-21), leaving 103 citations for further full text
evaluation. Upon further review, 73 articles were elimi-
nated (29 described survival analysis of miR-21 with
DFS, RFS or CSS; 17 did not give sufficient survival data;
2 had the overlapping data sets; 3 had a very small
sample size; 4 lacked full text; 18 detected miR-21 ex-
pression the index from serum or plasma). Then after
sensitive analysis as follows, three publications were
removed. As a result, 27 eligible studies [11,13,30-55]including 31 cases were included for the final analysis.
The flow chart for the studies is shown in Figure 1.
The basic characteristic descriptions of the 36 eligible
studies are summarised in Table 1. Briefly, these studies
were conducted in 11 countries (13 cohorts were Asian
populations and 18 cohorts were European and American
populations, and they were published between 2003 and
2014. Study sample sizes ranged from 25 to 345 patients
(median sample size, 105.5 patients). A total of 18 cohorts
were of I-IV stage or of all stages. Most studies investi-
gated miR-21 by quantitative reverse-transcription poly-
merase chain reaction (qRT-PCR). Overall, 21 cohorts
reported miR-21 as an indicator of poor prognosis, while
the other 10 showed no significant impact of miR-21 on
overall survival.
Quality assessment and meta-analysis
REMARK was used a guideline rather than a scoring
scale, so the assessment was a qualitative process rather
than a quantitative one (Additional file 2: Table S2). In-
stead of grading every published report and ranking their
quality as "high" or "low", we carried out an assessment
emphasising the analysis and presentation of the studies
to prevent the inclusion of inferior data which would in-
fluence the accuracy of the meta-analysis. Two studies
were eliminated during this procedure due to their small
sample size and poor quality of data [12,59]. In addition,
when using the random-effects model due to the signifi-
cant heterogeneity of the studies, dismal survival out-
comes were observed for tumour patients with miR-21
overexpression. The pooled HRs and CIs were 2.27(1.81-
2.86), with I2 values of 76.0%, and Figure 2 shows the re-
sults of the forest plot explained above.
Assessment of heterogeneity and subgroup analysis
Highly significant heterogeneity was detected when all
studies were pooled (I2 = 76.0%), signifying that the vari-
ation was due to heterogeneity rather than chance. To
make a conservative estimate, a random-effect model ra-
ther than a fixed-effect model was used to account for
the highly significant inter-study heterogeneity to sum-
marise the prognostic value of miR-21 across studies.
When all study populations were combined, dismal sur-
vival outcomes were observed with the overexpression
of miR-21 (Figure 2). There was evidence of significant
inter-study heterogeneity (p = 0.001, I2 = 76.0%).
Considering the substantial heterogeneity exhibited in
the trials aggregated with respect to the overall survival,
meta-regression and subgroup analyses were conducted
to explore the heterogeneity of the covariates including
the publication year, study location, number of patients,
mean age, follow-up, cut-off value of miR-21, cancer cat-
egory and stage (Table 2). Ultimately, the study age
might be a source of heterogeneity (Adj R2 = 10.63%).
Figure 1 Flow diagram illustrating the screening and selection process.
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population was 2.27(1.81,2.86) with I2 = 76.0%. We also
tried to use other grouping terms to explore the prog-
nostic role of miR-21, such as TNM stage, publication
year, CEA (cut-off value) et al. However, no clinical sig-
nificance could be found.
Sensitivity analysis and publication bias
The Begg's funnel plot method was applied to detect publi-
cation bias in the meta-analysis. No bias was found in any
of the included studies (p =0.174) (Figure 3). In addition,
sensitivity analysis was also conducted (Additional file 3:
Figure S1), and we found that when three studies with four
cases [34,40,54] were discarded, the outcome of the sensi-
tivity analysis was more stable.
Discussion
Accurate prognostic factors and their predictive functions
are particularly valuable in patients with some specific
types of cancer which have widely varying outcomes and
for which systemic adjuvant therapy might be important.
The differentiation of high-risk patients from low-risk pa-
tients may help us make a sensible decision to balance
treatment with further adjuvant therapy and the toxicside-effects inflicted on patients [60]. MiR-21 is an exciting
potential new biomarker of prognosis in malignancies, and
molecular studies have been encouraging. While some
studies found that miR-21 was significantly associated
with patient survival, other studies did not find any signifi-
cant results for miR-21.
Although a similar meta-analysis on the prognostic
value of miR-21 in various types of cancer was reported
three years ago [61], there were several problems with
the analysis that adversely impacted its quality. First, this
study did not describe the heterogeneity among the eli-
gible studies, while the between-study heterogeneity
would have a profound influence on the validity of the
conclusion. Second, the up-regulation of miR-21 was
found in both tumour tissues and non-tumour tissues
such as plasma and serum; however, in the absence of a
proven correlation between these two sources of tissues,
it is not rational to combine their results together with-
out any explanation or discussion [62]. Third, one eli-
gible study emphasised the interaction and combined
effect of miR-21 and other factors instead of the inde-
pendent role of miR-21 in prognosis [63]. In addition,
numerous studies on the association between miR-21
and prognosis have emerged since this meta-analysis
Table 1 Baseline characteristics of the eligible studies evaluating miR-21 expression and OS









Nagao 2012 [17] PDAC Other 79 Japan I-IV 65 40 NG Mean qRT-PCR
Shibuya 2010 [31] CRC Digestive 156 Japan *A-D 65 60 Normal
tissues&
Mean qRT-PCR
Gao 2010 [11] NSCLC Respiratory 47 China I-III 64 60 Normal
tissues
Median qRT-PCR
Childs 2009 [32] HNSCC Other 104 USA I-IV 60 60 Normal
tissues
Mean qRT-PCR
Yan 2008 [33] BC Breast 113 China I-III 48 66.2 Normal
tissues
Mean qRT-PCR
Lee 2011 [35] BC Breast 109 Korea I-III 48 100 NG Mean qRT-PCR
Jiang 2011 [36] Melanoma Other 106 China I-IV 60 60 NG Median qRT-PCR
Zhi 2010 [37] Astrocytoma Other 124 China I-IV 47.8 35.2 NG Median qRT-PCR
Jamieson 2012 [38] PDAC Other 58 UK II,III 65 23.9 Normal
tissues
Median qRT-PCR





Schetter 2008 [39] CRC Digestive 113 HK I-IV 55.8 84.6 Normal
tissues
Dichotomize Microarray
Faltejskova 2012 [41] CRC Digestive 44 Czech I-IV 67 84 Normal
tissues
Median qRT-PCR
Chen 2013 [42] CRC Digestive 195 Taiwan I-IV 66 60 Normal
tissues
Mean qRT-PCR
Toiyama 2013 [43] CRC Digestive 186 Japan I-IV 67 60 Normal
tissues
0.0031 qRT-PCR
Markou 2008 [13] NSCLC Respiratory 48 USA I-IV 60 50 Healthy
controls
2-fold qRT-PCR
Liu2012 [44] NSCLC Respiratory 70 China I-IV 60 30 Healthy
controls
2-fold qRT-PCR
Saito2011 [45] NSCLC Respiratory 89 USA I-III 63.6 80 Normal
tissues
Median qRT-PCR
Saito2011 [45] NSCLC Respiratory 37 Norway I-III 64.4 80 Normal
tissues
Median qRT-PCR
Saito2011 [45] NSCLC Respiratory 191 Japan I-III 59.6 80 Normal
tissues
Median qRT-PCR
Markou 2013 [46] NSCLC Respiratory 48 Greece I-IV 60 40 Normal
tissues
6.3-fold qRT-PCR





PC Other 88 Greece I-IV 66.5 40 Normal
tissues
Mean qRT-PCR
Karakatsanis2011 [48] HCC Digestive 60 Greece I-IV 60 50 Healthy
controls
Mean qRT-PCR
Kadera2013 [49] PDAC Other 153 USA I, II,IV 65 42 Healthy
controls
Median ISH
Markou 2014 [58] BC Breast 112 Greece 60 75 Normal
tissues
Median qRT-PCR
Akagi2013 [50] LC Respiratory 67 USA I 64.9 60 Normal
tissues
Median qRT-PCR
Akagi2013 [50] LC Respiratory 25 Norway I 64.0 60 Normal
tissues
Median qRT-PCR
Bovell2013 [51] CC Digestive 345 USA IV 65 17 Normal
tissues
Mean qRT-PCR
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Table 1 Baseline characteristics of the eligible studies evaluating miR-21 expression and OS (Continued)
Capodanno 2013 [52] NSCLC Respiratory 80 Italy I-IV 67 32 Normal
tissues
Median qRT-PCR





Mathe 2009 [55] ESCC Digestive 69 Two
countries
I-IV 62 62.5 Normal
tissues
Dichotomize qRT-PCR
Abbreviations: PDAC pancreatic ductal adenocarcinoma, CRC colorectal cancer, NSCLC non-small cell lung cancer, HNSCC head and neck squamous cell carcinoma,
CC colon cancer, RC rectal cancer, HCC hepatocellular carcinoma, ESCC oesophageal squamous cell carcinoma, BC breast cancer, PC pancreatic cancer, RCC renal
cell carcinoma, *Duke’s stage, ISH In Situ Hybridization, NG Not given, &Adjacent noncancerous tissues were procured from patients.
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systematic review and meta-analysis on this issue was
deemed essential. We were able to conduct our meta-
analysis on a larger sample size and with a more appro-
priate method to accurately evaluate the role of miR-21
in the prognosis of cancer.Figure 2 Meta-analysis of the association between miR-21 expression a
between miR-21 and overall cancer survival. The squares represent the size of
CIs. A random effects (RE) model was used, and the x-axis shows the Hazard rWhen we stratified the studies according to the differ-
ent possible contributors through meta-regression and
subgroup analysis, none of the studies had a definitive
explanation for the heterogeneity. Generally, the high
degree of heterogeneity was probably due to the differ-
ence in the baseline characteristics of the includednd prognosis. Meta-analysis of the forest plot showing the association
the study and are centred on the HR. The whiskers represent the 95%
atio.
Table 2 Meta-regression and subgroup analysis of the studies reporting the association between microRNA-21 and the
overall survival of cancer patients
Stratified study No. of
studies
Pooled HR(95% CI) Meta-regression Heterogeneity
Fixed-Model Random-Model Tau2 Adj R2 (%) p-value I2 (%) p-value
Year 0.246 3.79 0.350
>2012 17 2.48(2.17,2.83) 2.46(2.02,2.99) 43.0 0.031
≤2012 14 1.53(1.29,1.81) 2.13(1.36,3.31) 83.3 0.001
CEA (cut-off value) 0.268 −4.75 0.848
Mean & Median 25 2.06(1.84,2.30) 2.31(1.77,3.03) 80.4 0.001
Others 6 2.11(1.53,2.92) 2.11(1.53,2.92) 0.0 0.822
Sample size 0.268 −4.48 0.216
>100 15 1.85(1.53,2.22) 2.53(1.59,4.02) 82.1 0.001
<=100 16 2.18(1.92,2.48) 2.12(1.67,2.69) 66.4 0.001
Race 0.260 −1.68 0.537
Yellow 12 2.63(2.26,3.07) 2.67(2.07,3.42) 50.9 0.021
White 18 1.63(1.41,1.88) 1.94(1.40,2.71) 78.7 0.001
Age 0.229 10.63 0.391
<=60 12 2.42(2.08,2.82) 2.52(2.08,3.06) 32.2 0.088
>60 19 1.80(1.56,2.07) 1.90(1.21,3.01) 87.9 0.001
TNM stage 0.263 −2.78 0.362
I-IV 17 1.98(1.76,2.23) 2.16(1.16,2.92) 80.3 0.001
Others 14 1.22(1.15,1.30) 1.86(1.53,2.26) 80.7 0.001
Cancer category 0.258 −0.55 0.421
Digestive system 13 2.35(1.96,2.81) 2.43(1.95,3.03) 28.1 0.162
Respiratory system 11 1.82(1.47,2.26) 2.08(1.40,3.08) 66.9 0.001
Breast cancer 3 3.07(1.88,5.01) 4.08(1.23,13.48) 81.4 0.005
Others systems 4 1.89(1.60,2.25) 1.68(0.76,3.73) 95.0 0.001
Detect Method 0.270 −5.34 0.686
qPCR 29 2.27(1.81,2.86) 2.07(1.86,2.29) 76.0 0.001
others 2 ———— ———— ———— ———— ————
Overall 31 2.07(1.86,2.29) 2.27(1.81, 2.86) 76.0 0.001
Abbreviations: CI confidence interval, HR hazard ratio.
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stage, race or location, the sample size, the detection
methods and the duration of follow-up). In addition, the
lack of detailed information about baseline characteris-
tics as a result of non-standardised reporting likely con-
tributed to diversity across the studies as well. Moreover,
studies that do not extend their analysis beyond univari-
ate survival analysis are therefore less valuable because
these confounders between miR-21 and OS did not
distribute equally in each group for the variations in
author's clinical experience, adjustment method and the
innate characteristics of different cancers. These issues
contribute to inaccuracies associated with HR estima-
tion, and therefore, the pooling of results may produce
bias and heterogeneity. As a result, the diversification of
adjusted factors across studies along with a statisticaladjustment for the different clinicopathologic factors in-
cluded in multivariate analysis might have contributed
to the significant heterogeneity.
In addition, traditional survival analysis techniques
(Kaplan-Meier, log-rank test) rely on variable dichotomi-
sation into high or low values or splitting variables into
multiple bins. In addition, cut-off point selection itself
could potentially influence the prognostic value of the
proposed association [47]. Due to the lack of a clear and
widely agreed upon cut-off definition, the researchers
preferred to arbitrarily create one themselves in the la-
boratory, so the cut-off point and the accuracy of the
value varied between studies [24]. All of the above cases
made the interpretation difficult because patients with
the same values would be considered to have high
miR-21 expression in some studies but low expression in
Figure 3 Begg’s funnel plot of publication bias. Funnel plot for
the visual assessment of the presence of publication bias associated
with all of the studies included in the meta-analysis. The funnel graph
plots the log of the hazard ratio (HR) against the standard error of the
log of the HR (an indicator of the sample size). The open circles
indicate the individual studies. The line in the centre represents the
pooled HR. Egger’s test for publication bias was not significant
(p = 0.174).
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http://www.biomedcentral.com/1471-2407/14/819others [64]. In essence, estimates derived from different
tumour analyses are not comparable, not to mention
that they should not be combined in a meta-analysis.
Therefore, the assessment of miR-21 expression must be
considered to be a potential source of heterogeneity.
Thus, adopting a consensus cut-off value for miR-21 ex-
pression could facilitate the replication of results. For
miR-21 to be a useful predictive biomarker in clinical
practice, a single clearly defined protocol needs to be de-
veloped and validated to allow the comparison of out-
comes across studies.
Although the Begg’s test suggested a p value of 0.174,
the funnel plot provides some slight evidence of asym-
metry between the included studies, which indicates that
some epidemiological research bias exists. We attempted
to minimise publication bias by performing the literature
search as completely as possible using PubMed and
Chinese Biomedicine databases, without language or date
of publication restrictions. However, limitations still existed
as the total number of included studies and the total sam-
ple size were relatively small. In addition, we did not ex-
tend the search to unpublished data that would likely
include increased proportions of null results. Positive re-
sults tend to be more acceptable by journals, whereas
negative results are often rejected or are not even submit-
ted for review. As already highlighted, the negative studies
reported less detailed results, making them unlikely to be
evaluated. What's more, the language of publication also
introduced bias because positive results tend to be pub-
lished in English-language journals. Although our search
was conducted without language restriction, all of the
studies included in the meta-analysis were published inEnglish. As is known to all, the line across the top of a
funnel should be representative of the pooled effect.
Our study identified several limitations that must be
addressed. First, inadequate sample size was a frequent
problem in the studies included in our analyses, with
only 15 of the 31 studies reporting outcomes from over
100 patients. While pooling data may in part address de-
ficiencies in individual study sample size, smaller studies
are more likely to generate heterogeneity, as we ob-
served. Second, our study used data from published
studies rather than individual patient data (IPD), which
limited our ability to explore the potential for confound-
ing by various demographic and clinical factors (e.g.,
ethnicity, disease stage, differentiation and treatment re-
gimes). By contrast, IPD based meta-analysis can be used
to analyse all of the data in a consistent manner and in-
cludes data from unpublished studies. A careful collab-
orative reanalysis of the raw data from several good
studies may be more valuable than a more superficial re-
view that mixes good and poor studies [64]. Addition-
ally, this study was predominantly based on the findings
of observational studies. In particular, a considerable
portion of the included studies were retrospectively ac-
crued cohorts, which inherently contained greater po-
tential for confounding than do randomised controlled
trials. This issue led to conflicting results and also influ-
enced the authentic prognostic value of miR-21 alter-
ations, providing a lower level of evidence than desired.
In addition, four publications had a slightly shorter
follow-up time with a duration less than three years.
However, we found that in the Capodanno study (2013)
and Bowell study (2013), the majority of patients were
diagnosed with locally advanced disease. Pancreatic
ductal adenocarcinoma (PDAC, Jamieson [38]) and as-
trocytoma (Zhi [37]), of which grade III and IV consti-
tute 62% of cases, are two of the most aggressive
malignancies. The prognosis of these patients is quite
poor. Finally, quality assessment tools for examining
prognostic and predictive biomarker studies do not cur-
rently exist [65], and published articles have often lacked
sufficient information to allow an adequate assessment
of the quality of the study or the generalisation of the
study results. The quality of pooled studies significantly
influences the level of confidence of meta-analyses.
Therefore, we performed a methodological assessment
of the studies to avoid including some poor quality studies
in general instead of scoring each individual study [65] ac-
cording to the REMARK method [25,27] and the explan-
ation and elaboration that were recently published [66].
Conclusion
MiR-21 overexpression was found to be associated with
decreased overall survival in patients with a wide variety
of tumour categories in the present systematic review
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who received surgical treatment without any adjuvant
therapy, the miR-21 expression status is a direct out-
come of cancer itself and reflected the impact of miR-21
on cancer progression. Therefore, MiR-21 expression is
a potentially useful biomarker for predicting prognosis
and is a promising prognostic tool to help clinicians
make difficult therapeutic decisions. In addition, al-
though we excluded studies that did not include suf-
ficient survival data, we noted that some of them
contain negative conclusions about the prognostic role
of miR-21. Therefore, large adequately designed pro-
spective studies, both observational cohorts and clinical
trials that employ standard methodology, are now ur-
gently needed to substantiate our conclusions. The exact
role of miR-21 expression needs to be determined by an
appropriate multivariate analysis taking into account the
classical well-defined prognostic factors for each type of
cancer. Additionally, international consensus is urgently
required to mandate a homogeneous miR-21 assessment
methodology, to enable comparisons and the combin-
ation of large, prospectively planned individual patient
data meta-analyses. These types of studies may help de-
termine if miR-21 expression might be more appropriate
and better used in clinical decision-making for tumour
patients.
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